Jena/Germany, Oberkochen/Germany | 22 March 2017 | Carl Zeiss Meditec AG
At this year’s International Dental Show (IDS) in Cologne the Medical Technology Business Group of ZEISS is presenting EXTARO 300. It is poised to revolutionize and differentiate dental practices with Augmented Visualization, Digital Patient Communication and Single-Handed Operation.
Seeing more can help practitioners generate better outcomes and manage difficult cases. “We are delighted that the augmented visualization of EXTARO® 300 will support dentists in restorative dentistry, endodontics and all fields of dental surgery to achieve the highest level of performance and results – both functionally and aesthetically,” says Dr. Ludwin Monz, President and CEO of Carl ZEISS Meditec AG.
As the first device combining caries detection technology1 with optical magnification it allows the efficient repair of caries-infected fillings. The Fluorescence Mode in ZEISS EXTARO 300 supports identification of decayed tooth tissue in previously treated cavities2.
Assoc. Prof. Marko Jakovac, School of Dental Medicine in Zagreb, reports: "The breakthrough visualization modes of ZEISS allow us to introduce new applications to microdentistry. For removal of old restorations the autofluorescence functionality of ZEISS helps me to locate the decay as quickly as possible and to avoid removal of healthy tooth substance.“
Additionally, the Fluorescence Mode in ZEISS EXTARO 300 is designed to distinguish between natural hard tooth tissue and the most commonly used dental composite resins. This clear visual differentiation will help target the affected area quickly, saving valuable chair time during excavation.
ZEISS EXTARO 300 simplifies the tooth restoration workflow. The TrueLight Mode provides sufficient time to finish complex modeling tasks by preventing the premature curing of composites3 under the microscope. Unlike with orange filters, the new optimized color balance still allows dental specialists to identify relevant dental tissues.
The ZEISS Connect App helps dental practitioners to inform patients both about treatment needs and accomplished results. The digital workflow of ZEISS EXTARO 300 facilitates clinical case documentation and is conveniently integrated into the digital office.
“ZEISS EXTARO 300 not only allows dentists to see more and to provide more efficient treatment,” says Dirk L. Brunner, Senior Vice President, Microsurgery Division Medical Technology Business Group, “it also ensures an uninterrupted workflow, as all functions can be operated by one hand.”
All capture and visual modes can be activated at the push of a button, plus dentists can adjust the unprecedented working distance range with only one finger. Making ZEISS EXTARO 300 part of the dental practice not only helps improve comfort, but also makes treatment more efficient. More ergonomic and comfortable working conditions can also increase the longevity of a dentist's practicing career.
1 Jahrbuch der Endodontie 2017, Marktübersicht Mikroskope, OEMUS Verlag
2 Fluorescence Mode for caries detection is not available for sale in the US, requires 510(k) clearance by the U.S. FDA and may be subject to change. Not for sale in every market.
3 For specifications see user manual
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 2,900 employees worldwide, the Group generated revenue of € 1,088 million in financial year 2015/16 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med